Lynch综合征的遗传学与临床意义
Lynch综合征(LS)是最常见的遗传性癌症综合征之一,约占未选择性结直肠癌或子宫内膜癌患者的3%,占DNA错配修复缺陷肿瘤患者的10%-15%。本文综述LS的流行病学、临床和分子信息进展,讨论基因型和免疫亚型特异的监测、癌症预防和治疗策略。
要点
- LS约占未选择性结直肠癌或子宫内膜癌患者的3%,占DNA错配修复缺陷肿瘤患者的10%-15%。
- LS肿瘤分子发病机制的认识近期有重要进展,对临床管理有重要意义。
- 免疫治疗已革新DNA错配修复缺陷晚期癌症的治疗。
核心结论
- 不断积累的流行病学、临床和分子信息有助于更准确和完整地认识LS,从而制定基因型和免疫亚型特异的监测、癌症预防和治疗策略。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- LS约占未选择性结直肠癌或子宫内膜癌患者的3%,占DNA错配修复缺陷肿瘤患者的10%-15%。
- LS肿瘤分子发病机制的认识近期有重要进展,对临床管理有重要意义。
- 免疫治疗已革新DNA错配修复缺陷晚期癌症的治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lynch syndrome (LS) is one of the most prevalent hereditary cancer syndromes in humans and accounts for some 3% of unselected patients with colorectal or endometrial cancer and 10%-15% of those with DNA mismatch repair-deficient tumors. Previous studies have established the genetic basis of LS predisposition, but there have been significant advances recently in the understanding of the molecular pathogenesis of LS tumors, which has important implications in clinical management. At the same time, immunotherapy has revolutionized the treatment of advanced cancers with DNA mismatch repair defects. We aim to review the recent progress in the LS field and discuss how the accumulating epidemiologic, clinical, and molecular information has contributed to a more accurate and complete picture of LS, resulting in genotype- and immunologic subtype-specific strategies for surveillance, cancer prevention, and treatment.
引用
- Peltomäki P, Nyström M, Mecklin JP, et al. Lynch Syndrome Genetics and Clinical Implications. Gastroenterology. 2023. PMID: 36706841. doi:10.1053/j.gastro.2022.08.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。